130643-07-1

Usage

Uses

Used in Pharmaceutical Industry:
6-OXA-9-AZASPIRO[4.5]DECANE is used as a reactant for the preparation of spiro-tetracyclic ring compounds. These compounds are of significant interest in the pharmaceutical industry as they serve as therapeutic secretase modulators. Secretase modulators are crucial in the treatment of various neurodegenerative diseases, such as Alzheimer's disease, by regulating the production of amyloid-beta peptides, which are implicated in the pathology of these conditions.

InChI:InChI=1/C8H15NO/c1-2-4-8(3-1)7-9-5-6-10-8/h9H,1-7H2

Upstream product

• 271245-39-7 1,1-dimethylethyl 6-oxa-9-azaspiro[4.5]decane-9-carboxylate 
• 45511-81-7 1-(aminomethyl)-1-hydroxycyclopentane 
• 5117-85-1 1-hydroxycyclopentanecarbonitrile 
• 120-92-3 cyclopentanone 

Downstream Products

• 1245465-34-2 9-({5-[6-bromo-1-(phenylsulfonyl)-1H-indazol-4-yl]-1,3,4-oxadiazol-2-yl}methyl)-6-oxa-9-azaspiro[4.5]decane 
• 1245465-92-2 C₃₂H₃₀N₆O₄S 
• 1245466-41-4 C₃₁H₃₃N₇O₇S₂ 

Relevant academic research and scientific papers

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

Indazole derivatives for use in the treatment of influenza virus infection

The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.

4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.